Infectious Diseases
Conference Coverage
Hep C sofosbuvir/daclatasvir combo promising for COVID-19
“We need to remember that conducting research amidst a pandemic with overwhelmed hospitals is a clear challenge, and we cannot be sure of success...
Latest News
Hyperglycemia predicts COVID-19 death even without diabetes
This finding came from a retrospective analysis of 605 patients with COVID-19 seen at two hospitals in Wuhan, China.
From the Journals
Infants around the world with bronchiolitis received excess tests despite guidelines
While antibiotic use was relatively rare in this global cohort, chest x-rays, blood tests, and other nonrecommended interventions were common.
Conference Coverage
Influenza vaccine efficacy called undiminished in MS
Meta-analysis results are consistent with latest AAN immunization guideline.
Conference Coverage
Diagnosing molluscum contagiosum can be tricky
The viral disorder brings its own eczematous response, which can complicate efforts to confirm the diagnosis.
Conference Coverage
Injection beats pill for long-lasting HIV prevention
The findings “could transform the HIV prevention landscape for so many people,” said Megan Coleman, DNP.
From the Journals
Children rarely transmit SARS-CoV-2 within households
Most children with COVID-19 disease are infected inside family groups, but are not the initial transmitters.
From the Journals
Even a few days of steroids may be risky, new study suggests
A retrospective study of more than 2.6 million Taiwanese adults echoes findings from a 2017 cohort study of more than 1.5 million U.S. adults.
Commentary
International medical graduates facing challenges amid COVID-19
Prospective residents, graduating residents, and fellows need the ability to join the American health care system promptly, the authors say.
Feature
‘Doc, can I get a mask exemption?’
"It makes sense to say that if it makes you uncomfortable to wear a mask because it affects your breathing, you should think twice about getting...
Conference Coverage
Neural tube defect risk from dolutegravir drops as clinical experience grows
A troubling link between the top HIV drug dolutegravir and neural tube defects, first reported in 2018, now seems much less dangerous.